196 related articles for article (PubMed ID: 11354391)
1. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate.
Kaye CM; Allen A; Perry S; McDonagh M; Davy M; Storm K; Bird N; Dewit O
Clin Ther; 2001 Apr; 23(4):578-84. PubMed ID: 11354391
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation.
Löwdin E; Cars O; Odenholt I
Clin Microbiol Infect; 2002 Oct; 8(10):646-53. PubMed ID: 12390283
[TBL] [Abstract][Full Text] [Related]
3. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
Berry V; Hoover J; Singley C; Woodnutt G
Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
Odenholt I; Cars O; Löwdin E
J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
[TBL] [Abstract][Full Text] [Related]
5. New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.
Sánchez Navarro A
Clin Pharmacokinet; 2005; 44(11):1097-115. PubMed ID: 16231964
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and intramuscular administration to pigeons.
Escudero E; Vicente MS; Carceles CM
Res Vet Sci; 1998; 65(1):77-81. PubMed ID: 9769077
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
8. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
Jacobs MR
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet.
Sourgens H; Steinbrede H; Verschoor JS; Bertola MA; Rayer B
Int J Clin Pharmacol Ther; 2001 Feb; 39(2):75-82. PubMed ID: 11270805
[TBL] [Abstract][Full Text] [Related]
11. Proof of concept: performance testing in models.
Craig WA
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():12-7. PubMed ID: 14759229
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
Pottumarthy S; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
Anon JB; Ferguson B; Twynholm M; Wynne B; Berkowitz E; Poole MD
Ear Nose Throat J; 2006 Aug; 85(8):500, 502, 504 passim. PubMed ID: 16999056
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
Sethi S; Breton J; Wynne B
Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on amoxicillin/clavulanic acid 2000 mg/125 mg extended release (XR) in respiratory tract infections in adults.
McCormack PL; Keating GM
Treat Respir Med; 2005; 4(5):361-2. PubMed ID: 16137193
[TBL] [Abstract][Full Text] [Related]
16. Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy volunteers.
Ponte C; Gracia M; Giménez MJ; Aguilar L; Maín CM; Carpintero Y; Huelves L; Carcas A; del Prado G; Soriano F
Clin Ther; 2005 Jul; 27(7):1043-9. PubMed ID: 16154483
[TBL] [Abstract][Full Text] [Related]
17. Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of Clavubactin and Synulox in healthy dogs.
Vree TB; Dammers E; Van Duuren E
J Vet Pharmacol Ther; 2003 Jun; 26(3):165-71. PubMed ID: 12755899
[TBL] [Abstract][Full Text] [Related]
18. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.
Easton J; Noble S; Perry CM
Drugs; 2003; 63(3):311-40. PubMed ID: 12534334
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics study of amoxycillin and clavulanic acid (8:1)--a new combination in healthy Chinese adult male volunteers using the LC-MS/MS method.
Zhang J; Wang Y; Xie H; Wang R; Jia Z; Men X; Xu L; Zhang Q
Cell Biochem Biophys; 2013 Apr; 65(3):363-72. PubMed ID: 23109176
[TBL] [Abstract][Full Text] [Related]
20. Amoxicillin/clavulanic acid 2000mg/125mg extended release (XR): a review of its use in the treatment of respiratory tract infections in adults.
McCormack PL; Keating GM
Drugs; 2005; 65(1):121-36. PubMed ID: 15610061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
